Concurrent Weekly Cisplatin Versus Triweekly Cisplatin with Radiotherapy in the Treatment of Cervical Cancer: A Meta-analysis Result

Abstract

Aims: To evaluate the adverse effect and survival outcome of weekly and triweekly cisplatin with radiotherapy in treatment of cervical cancer. Methods: After an extensive literature search between 1995-2011,we analyzed 7 studies to compare weekly cisplatin and triweekly cisplatin combined radiotherapy. Results: Our analysis established that weekly cisplatin has a lower risk of hematologic toxicity than triweekly cisplatin with concurrent radiotherapy in the treatment of cervical cancer. However, there were no differences in progression free survival and overall survival between weekly cisplatin and triweekly cisplatin (p>0.05). Conclusions: Weekly cisplatin combined with concurrent radiation has lower risk in hematologic toxicity than triweekly cisplatin, but does not improve survival. Triweekly cisplatin treatment has longer intervals and is therefore more convenient. Clinicians and patients can choose either weekly cisplatin or triweekly cisplatin combined radiotherapy for cervical cancer.

Chemoradiation Related Acute Morbidity in Carcinoma Cervix and Correlation with Hematologic Toxicity: A South Indian Prospective Study

“…To be more precise, it appears that it is the chemotherapy that predominantly contributes to hematologic changes and radiotherapy that results in gastrointestinal and other toxicities. This argument is indirectly supported by the observations in the studies by Hu et al (2012) where it was found that the hematologic toxicity was less with weekly cisplatin (40mg/m 2 ) compared to triweekly cisplatin (75 mg/m 2 ) and that the other toxicities did not show any difference with the two regimens.…”

Weekly Versus Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Cervical Cancer: A Meta-Analysis

“…In order to analyze systematically which regimen is better, a meta-analysis has been conducted to compare differences between weekly and triweekly cisplatin arms. 11 Nevertheless, the studies evaluated in the research are not all randomized controlled trials (RCTs), along with 2 of the articles from different stages of the same study, which impairs validity and credibility of the result. Consequently, the aim of this study was to evaluate adverse effect and survival of 2 regimens more fully and precisely.…”

Efficacy and Safety Evaluation of the Various Therapeutic Options in Locally Advanced Cervix Cancer: A Systematic Review and Network Meta-Analysis of Randomized Clinical Trials

“…95 The potential benefit of weekly versus 3-weekly cisplatin-based concurrent CTRT in LACC has also been investigated in 2 meta-analyses. 122,123 and a retrospective single-institution review. 124 The conclusions from these studies are blurred because of the inclusion of both singleagent cisplatin and mostly combination regimes in a triweekly arm and the inclusion of retrospective studies with adjuvant CTRT in patients postoperatively.…”